Medtronic Aktie News

The recent high-velocity sell-off may be a preview of what's to come this year or in 2026.

Abbott and Medtronic are innovative healthcare leaders that generate consistent revenue and profits. They also have attractive long-term prospects and have consistently raised their dividend payouts.

Futures are trading higher this morning, as all the major indices once again closed lower on Tuesday, marking the fourth straight day of losses.

The critical details are that price action cleared a crucial hurdle in early 2025, formed a Golden Crossover, and confirmed a completed market reversal following the fiscal year 2026 (F2026) Q2 earnings release.

Shares of a major home improvement retailer lost ground after it missed quarterly profit forecasts, indicating homeowners are putting off remodeling projects amid economic uncertainty. Meanwhile, strong demand and procedure volumes helped drive a strong earnings report for a medical device company, and its shares advanced.

Drugmakers are making notable deals, biotech is coming back, and much of the worry about tariffs and interest rates has faded away.

Medtronic plc ( MDT ) Q2 2026 Earnings Call November 18, 2025 8:00 AM EST Company Participants Ryan Weispfenning - VP & Head of Investor Relations Geoffrey Martha - Chairman of the Board & CEO Thierry Pieton - Executive VP & CFO Laura Mauri - Senior VP and Chief Scientific & Medical Officer Conference Call Participants Patrick Wood - Morgan Stanley, Research Division Travis Steed - BofA Securit...

Medtronic raised its fiscal-year outlook after logging higher profit and sales in its latest quarter, boosted by robust demand across end markets and healthy procedure volumes.